With Personalized Medicine, Payers Want A Role In Early Development
With the development of targeted therapies and companion diagnostics increasing, AmerisourceBergen Consulting’s president advises pharma industry to bring payers in around Phase II to ensure trials give them data they need to cover drugs and diagnostics.
You may also be interested in...
Three major drug makers inked broad alliances with the research departments of major US payers in 2011. The alliances signal that even as pharma reorients its R&D engines to be more flexible and externally focused in the hopes of shedding risk and cost, such moves are not enough.
As personalized medicine shifts from theory to practice, concerns are mounting about whether the evidence behind many biomarkers is sufficient to make pharmacogenomic testing worthwhile – suggesting sponsors should pay careful attention to providing evidence to support use of companion diagnostics.
Companion diagnostics and biomarkers were the watchwords of the recent ASCO meeting as the cancer community braces for a sea change in treatment. But as more targeted drugs and companion diagnostics make it through the clinical and regulatory arenas, payers will have to grapple with managing the more complex real-world use of these therapies.